|
|
|
|
||
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congresshttps://investors.atarabio.com/news-events/press-releases/detail/194/atara-biotherapeutics-to-present-late-breaking-ata188-data Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress Download as PDFMay 19, 2020 8:30am EDT Company to Host Live Conference Call and Webcast to Review Data Presentation on May 26, 2020 at 8:00 a.m. EDT/2:00 p.m. CEST Atara Resuming Enrollment in the Phase 1b Study After Brief COVID-19-Related Pause SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present updated safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking e-poster presentation at the 6th European Academy of Neurology (EAN) Annual Congress, held virtually from Paris, May 23-26, 2020. The Company will present six-month safety and efficacy clinical results for dose-escalating cohorts 1-4 and 12-month results for cohorts 1-3 in the late-breaking e-poster, including disability data with multi-scale disability and Expanded Disability Status Scale (EDSS). The abstract will become available on the EAN Website on May 22 at 12:30 p.m. EDT/6:30 p.m. CEST. With the acceptance and presentation of these data, Atara continues to deliver on key milestones. Building on this progress, Atara is resuming enrollment in the ATA188 Phase 1b study after a brief pause due to COVID-19-related precautions. Details of the 2020 EAN Virtual Congress Late-Breaking e-Poster Title: Phase 1 study of the safety and efficacy of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy to treat progressive forms of multiple sclerosis Poster #: LB130 Poster Session: EPO400 Availability: e-Poster, along with a three-minute audio recording, will be available from May 22 at 2:00 p.m. EDT/8:00 p.m. CEST through to the conclusion of the Congress on May 26 Atara Conference Call and Webcast Information Atara will hold a conference call at 8:00 a.m. EDT/2:00 p.m. CEST for analysts and investors to review the data, current disease and treatment landscape and Atara’s continued plans for the ATA188 program. The call will include: Amit Bar-Or, MD, FRCP, FAAN, FANA, Chief of MS Division, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics and Genetics, Stanford University Pascal Touchon, President and Chief Executive Officer, Atara Biotherapeutics Jakob Dupont, MD, Executive Vice President, Global Head of Research and Development, Atara Biotherapeutics AJ Joshi, MD, Senior Vice President and Chief Medical Officer, Atara Biotherapeutics Analysts and investors can participate in the conference call by dialing (888) 540-6216 for domestic callers and (734) 385-2715 for international callers, using the conference ID 3665248. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 30 days following the live webcast. |
return to message board, top of board |